SCHEMBL1744913

SCHEMBL1744913

CC(C)(C)OC(=O)CCCCCCCCCCCCCCC(=O)Nc1ccc(C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 7/20 0.61
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.49
HDAC1 Q13547 4/20 0.47
HDAC11 Q96DB2 4/20 0.47
HDAC6 Q9UBN7 4/20 0.47
HDAC3 O15379 4/20 0.47
HDAC2 Q92769 3/20 0.47
HDAC10 Q969S8 3/20 0.47
HDAC4 P56524 3/20 0.47
HDAC7 Q8WUI4 3/20 0.47
HDAC9 Q9UKV0 3/20 0.47
HDAC5 Q9UQL6 3/20 0.47
ALDH1A1 P00352 1/20 0.47
NCOR2 Q9Y618 3/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sebacic Acid SCHEMBL3905690 0.96 HDAC8 (0.57) HDAC8CYP1A2CYP2C9L3MBTL1HDAC1
SCHEMBL557990 0.88 HDAC8 (0.60) HDAC8L3MBTL1HDAC1HDAC11HDAC6
SCHEMBL25892570 0.87 HDAC8 (0.50) HDAC8CYP1A2CYP2C9HDAC1HDAC11
SCHEMBL31522340 0.86 HDAC8 (0.67) HDAC8CYP1A2CYP2C9L3MBTL1HDAC1
SCHEMBL24881075 0.86 HDAC8 (0.63) HDAC8L3MBTL1HDAC1HDAC11HDAC6
SCHEMBL1577613 0.86 CYP1A2 (0.59) HDAC8CYP1A2CYP2C9L3MBTL1HDAC1
SCHEMBL11031322 0.84 CYP1A2 (0.67) HDAC8CYP1A2CYP2C9L3MBTL1HDAC1
SCHEMBL30207564 0.83 HPGD (0.57) HDAC8CYP1A2CYP2C9HDAC1HDAC11
SCHEMBL557519 0.82 HDAC8 (0.51) HDAC8HDAC1HDAC11HDAC6HDAC3
SCHEMBL5243757 0.82 CA1 (0.59) HDAC8CYP1A2CYP2C9HDAC1HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386572-B1 Insulin derivative NOVO NORDISK AS (DK) 2015-07-08 EP disclosed
US-8933021-B2 Insulin derivative NOVO NORDISK A/S (DK) 2015-01-13 US disclosed
EP-2015770-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2012-09-26 EP disclosed
EP-2386572-A1 Insulin derivative Novo Nordisk A/S (DK) 2011-11-16 EP disclosed
US-8039101-B2 Radio-opaque dental prosthetic member Societe de Recherches Techniques Dentaires-R.T.D. (FR) 2011-10-18 US disclosed
US-20090239785-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-09-24 US disclosed
CN-101437849-A Insulin derivatives NOVO NORDISK AS (DK) 2009-05-20 CN disclosed
EP-2015770-A2 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-01-21 EP disclosed
WO-2007128817-A2 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239785-A1 Insulin Derivative IAPP, INSR, GPR119 HDAC8 3012/4885CYP1A2 2989/4885CYP2C9 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.